anyone else notice retatrutide kicking in around week 83
Reporting in. anyone else notice retatrutide kicking in around week 83.
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.
The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.
Happy to answer the boring questions. Those are usually the ones worth asking.
best — the order this archive was captured in
Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.
Watched heart rate on a wearable across twelve weeks because the threads said to. It moved a little and I have no idea whether that means anything.
Is that the 48-week figure or an earlier readout?
Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.
wait for phase 3 before you argue about rankings
the glucagon component is why the metabolic story reads differently
Has anyone posted an independent test on this compound recently?
What is the source for that figure — the published paper or a summary of it?
the escalation is where most of the reported trouble sits
Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.
nothing here is available as a prescription product, so read every thread with that in mind
Not convinced. You are attributing a week of sulphur burps to the glucagon arm when the escalation rate alone would explain it.
- 1wait for phase 3 before you argue about rankings7 comments in this branch · started by u/janek_ferrari